Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Operating Expenses (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Operating Expenses over the past 16 years, most recently at $8.6 million for Q2 2025.

  • For Q2 2025, Operating Expenses fell 43.37% year-over-year to $8.6 million; the TTM value through May 2025 reached $50.6 million, changed 0.18%, while the annual FY2025 figure was $50.6 million, 0.27% changed from the prior year.
  • Operating Expenses for Q2 2025 was $8.6 million at Lifecore Biomedical, Inc. \De\, down from $12.0 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $39.2 million in Q2 2021 and troughed at $7.8 million in Q4 2021.
  • A 5-year average of $13.9 million and a median of $11.7 million in 2023 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 454.82% in 2021 and later tumbled 73.87% in 2022.
  • Year by year, Operating Expenses stood at $7.8 million in 2021, then surged by 42.01% to $11.0 million in 2022, then grew by 3.71% to $11.4 million in 2023, then increased by 14.01% to $13.0 million in 2024, then plummeted by 34.34% to $8.6 million in 2025.
  • Business Quant data shows Operating Expenses for LFCR at $8.6 million in Q2 2025, $12.0 million in Q1 2025, and $13.0 million in Q4 2024.